Cediranib
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628 |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.505 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1]
It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
References
- ^ Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |